{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:41:53Z","timestamp":1790624513960,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21302097"],"award-info":[{"award-number":["21302097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Jiangsu Province","doi-asserted-by":"crossref","award":["14KJD350002"],"award-info":[{"award-number":["14KJD350002"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Program of Science and Technology Department of Jiangsu Province","award":["BE2014720"],"award-info":[{"award-number":["BE2014720"]}]},{"name":"National and Local Joint Engineering Research Center of Biomedical Functional Materials and Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ejmech.2017.04.036","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T15:21:20Z","timestamp":1492183280000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Design, synthesis, SAR discussion, in\u00a0vitro and in\u00a0vivo evaluation of novel selective EGFR modulator to inhibit L858R\/T790M double mutants"],"prefix":"10.1016","volume":"135","author":[{"given":"Haoyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enhe","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihe","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.04.036_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ErbB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2017.04.036_bib2","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2017.04.036_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signaling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.10.058","article-title":"Novel 2-chloro-4-anilino- quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors","volume":"71","author":"Barbosa","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3747\/co.v16i1.393","article-title":"The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement","volume":"16","author":"Ellis","year":"2009","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.04.036_bib7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.20909","article-title":"Protein overexpression and gene amplification of epidermal growth factor receptor in non-small cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study","volume":"103","author":"Suzuki","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2017.04.036_bib8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2016.08.068","article-title":"Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors","volume":"124","author":"Han","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejmech.2016.07.049","article-title":"Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity","volume":"123","author":"Amin","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejmech.2016.04.072","article-title":"Design, synthesis and biological evaluation of novel EGFR\/HER2 dual inhibitors bearing an oxazolo[4,5-g] quinazolin-2(1H)-one scaffold","volume":"120","author":"Yin","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib12","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1158\/0008-5472.CAN-04-1905","article-title":"Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255","volume":"64","author":"Tracy","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.04.036_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2017.04.036_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease","volume":"31","author":"Ohashi","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2017.04.036_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.04.036_bib17","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2017.04.036_bib18","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2017.04.036_bib19","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.04.036_bib20","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible Pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib21","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.04.036_bib22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2017.04.036_bib23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1021\/acs.jmedchem.5b01633","article-title":"Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants","volume":"59","author":"Cheng","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib24","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.04.036_bib25","first-page":"5s","article-title":"Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)","volume":"32","author":"J\u00e4nne","year":"2014","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/14737140.2016.1162103","article-title":"The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer","volume":"16","author":"Gao","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2017.04.036_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jsb.2015.10.018","article-title":"Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed","volume":"192","author":"Yosaatmadja","year":"2015","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib28","doi-asserted-by":"crossref","first-page":"8877","DOI":"10.1021\/acs.jmedchem.5b01412","article-title":"Noncovalent mutant selective epidermal growth factor receptor inhibitors: a lead optimization case history","volume":"58","author":"Heald","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.04.036_bib29","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/nbt896","article-title":"FRET imaging","volume":"21","author":"Jare-Erijma","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2017.04.036_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in\u00a0vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2017.04.036_bib31","first-page":"453","article-title":"Introduction to in\u00a0vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development","volume":"58","author":"Baranczewski","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2017.04.036_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2017.04.036_bib33","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.vascn.2011.03.031","article-title":"Cardiac ion channel safety profiling on the IonWorks Quattro system","volume":"64","author":"Cao","year":"2011","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2017.04.036_bib34","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417303008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417303008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T22:28:43Z","timestamp":1750199323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417303008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":34,"alternative-id":["S0223523417303008"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.04.036","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, SAR discussion, in\u00a0vitro and in\u00a0vivo evaluation of novel selective EGFR modulator to inhibit L858R\/T790M double mutants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}